NEO vs QGEN
NEO: NeoGenomics is a clinical laboratory leader providing specialized cancer-focused genetic and molecular testing services for diagnostics and pharmaceutical research. QGEN: QIAGEN supplies essential molecular diagnostic and sample preparation tools that enable laboratories and clinicians to detect, analyze, and validate genetic material and biomarkers.
Side-by-side fundamentals
| Metric | NEO | QGEN | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $13.14 | $41.40 | |
| Market cap as of 2026-08-03 | $1.7B | $8.5B | |
| P/E as of 2026-08-03 | n/a | 21.93 | |
| PEG as of 2026-08-03 | 1.27 | 3.48 | NEO lower |
| Net margin as of 2026-08-03 | -13.3% | +19.2% | QGEN higher |
| Gross margin as of 2026-08-03 | +43.1% | +62.6% | QGEN higher |
| Operating margin as of 2026-08-03 | -14.3% | +20.7% | QGEN higher |
| ROE as of 2026-08-03 | -11.8% | +11.3% | QGEN higher |
| ROA as of 2026-08-03 | -7.2% | +6.6% | QGEN higher |
| Debt / equity as of 2026-08-03 | 0.41 | 0.49 | NEO lower |
| Revenue growth (YoY) as of 2026-08-03 | +10.9% | +4.8% | NEO higher |
| Revenue CAGR (3y) SEC XBRL | n/a | -0.8% | |
| Dividend yield as of 2026-08-03 | n/a | +0.6% | |
| Dividend streak (yrs) SEC XBRL | n/a | 1 | |
| Beta as of 2026-08-03 | 1.78 | 0.47 | |
| 1-year return as of 2026-07-27 close | +108.9% | -16.1% | NEO higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.